Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Key Highlights
- ➤Zura granted options for up to 250,200 Class A Ordinary Shares to five new employees
- ➤Options carry a $3.56 exercise price, matching Zura’s October 26 closing price
- ➤Options vest over four years, with quarterly installments after the first anniversary
- ➤Zura’s lead candidate tibulizumab is in two Phase 2 autoimmune-disease studies
- ➤Zura plans to initiate its NEXUS-PMR Phase 2 study by year-end 2026
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on October 26, 2026, the Company granted inducement awards consisting of options to purchase up to 250,200 Class A Ordinary Shares (the “Options”) to five newly hired employees. These awards were approved by the Compensation Committee of the Company’s Board of Directors and granted outside the Company’s 2023 Equity Incentive Plan, as amended (the “Plan”), as inducements material to the new employees’ employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards are subject to the terms and conditions and other provisions set forth in the Company’s Plan and the award agreements thereunder.
Get started
Create a free account to read the full story.